STOCK TITAN

ARROWHEAD PHARMACEUTICALS (ARWR) SEC Filings, Jul-Aug 2025

ARWR NASDAQ
Rhea-AI Summary

Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 11,517,441 shares of Arrowhead Pharmaceuticals common stock, representing 8.3% of the outstanding class. The reported position includes 917,441 shares issuable upon exercise of warrants and the percentage is calculated on an aggregate of 138,100,435 shares outstanding as disclosed in the company's quarterly report.

The filing states Avoro holds sole voting and sole dispositive power over these shares and that the holdings are held for investment purposes on behalf of Avoro Life Sciences Fund LLC. The filing notes the report should not be construed as an admission of beneficial ownership for Section 13 purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
other
-
Rhea-AI Summary

Sarepta Therapeutics Investments, Inc., a wholly owned subsidiary of Sarepta Therapeutics, Inc., filed a Form 144 notice indicating a proposed sale of 9,265,312 shares of common stock of the issuer through Jefferies LLC on Nasdaq. The filing reports an aggregate market value of $185,213,586.88 and lists total shares outstanding as 138,257,550. The approximate date of sale is 08/13/2025.

The filing states these securities were acquired in a private placement from the issuer on 02/07/2025 by Sarepta Therapeutics Investments, Inc., with 11,926,301 shares acquired and payment made in cash on that date. The notice includes the standard representation that the person for whose account the securities are to be sold does not know of any undisclosed material adverse information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
other
-
Rhea-AI Summary

Form 144 filed for ARWR reports a proposed sale of 611 common shares through Merrill Lynch on the NASDAQ with an aggregate market value of $12,190.05 and 138,257,550 shares outstanding. The notice specifies an approximate sale date of 08/13/2025.

The filing lists the acquisition history for the shares being sold: grants received as compensation on 01/04/2022 (3,485), 01/02/2023 (15,802), 01/04/2023 (12,557), 01/04/2024 (1,167), 01/08/2024 (4,950) and 01/04/2025 (27,271), with the named transferor in those records shown as James Hamilton. The form indicates no securities sold in the past three months and includes the required representation that the seller does not possess undisclosed material information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
other
Rhea-AI Summary

Daniel Joseph Apel, Chief Financial Officer of Arrowhead Pharmaceuticals (ARWR), reported direct beneficial ownership of 101,200 shares of common stock. The filing specifies that this total includes 100,000 restricted stock units that will vest over four years, disclosed on an initial Form 3.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.30%
Tags
insider
-
Rhea-AI Summary

State Street Corporation filed a Schedule 13G reporting beneficial ownership of 6,371,056 shares of Arrowhead Pharmaceuticals Inc. common stock, representing 4.6% of the class as of the event date 06/30/2025. The filing is signed on behalf of State Street by Elizabeth Schaefer, Senior Vice President and Chief Accounting Officer, on 08/08/2025.

The statement shows no sole voting or dispositive power (0 shares) and records shared voting power of 5,952,902 shares and shared dispositive power of 6,371,056 shares. Item 7 identifies State Street advisory and funds entities as affiliated managers (for example, SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited). The filing does not indicate a group filing or identify any other person with >5% ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.81%
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
quarterly report
-
Schedule 13G/A
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
other
-
Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
other

FAQ

How many ARROWHEAD PHARMACEUTICALS (ARWR) SEC filings are available on StockTitan?

StockTitan tracks 79 SEC filings for ARROWHEAD PHARMACEUTICALS (ARWR), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for ARROWHEAD PHARMACEUTICALS (ARWR)?

The most recent SEC filing for ARROWHEAD PHARMACEUTICALS (ARWR) was filed on November 12, 2026.